Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6519549 | 0.97 | AVPR1B (0.73) | AVPR1BCYP3A4 | |
| SCHEMBL6523884 | 0.94 | AVPR1B (0.69) | AVPR1BCYP3A4 | |
| SCHEMBL6517829 | 0.93 | AVPR1B (0.71) | AVPR1BCYP3A4 | |
| SCHEMBL6523787 | 0.93 | AVPR1B (0.69) | AVPR1BCYP3A4 | |
| SCHEMBL6517567 | 0.92 | AVPR1B (0.71) | AVPR1BCYP3A4 | |
| SCHEMBL15641569 | 0.87 | AVPR1B (0.56) | AVPR1B | |
| SCHEMBL4085258 | 0.87 | AVPR1B (0.73) | AVPR1BCYP3A4 | |
| SCHEMBL1791162 | 0.87 | AVPR1B (0.56) | AVPR1B | |
| SCHEMBL15641573 | 0.86 | AVPR1B (0.56) | AVPR1B | |
| SCHEMBL1787520 | 0.86 | AVPR1B (0.56) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABBVIE DEUTSCHLAND (DE) | 2016-12-15 | — | — | US | disclosed |
| US-9422264-B2 | Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-23 | — | — | US | disclosed |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-10-23 | — | — | US | disclosed |
| US-8859557-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-10-14 | — | — | US | disclosed |
| US-8815868-B2 | Substituted oxindole derivatives and their use as vasopressin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2014-08-26 | — | — | US | disclosed |
| US-20120322809-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AbbVie Deutschland GmbH & Co. KG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | ABOTT GMBH & CO KG (DE) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362394-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885 |
| US-20140315914-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885 |
| US-20120322809-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN RECEPTOR LIGANDS | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 2791/4885 |
| US-20110065720-A1 | CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES | AVPR2, AVPR1B, AVPR1A | AVPR1B 2/4885CYP3A4 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.